NCT01331824 2018-04-23Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial CarcinomaIcahn School of Medicine at Mount SinaiPhase 2 Terminated22 enrolled 12 charts